Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation
https://doi.org/10.18087/cardio.2023.3.n2418
Abstract
A qualitative change in the risk profile after an episode of decompensated heart failure (HF) calls for an as immediate as possible therapeutic response. In the absence of uniform guidelines for the sequence and timing of administering the background therapy during the hospitalization period and the subsequent “vulnerable” period, clinicians have to rely on available expert opinions and results of conducted studies. The article focuses on an evidence base for the use of background therapy for HF during the above-mentioned periods. Special attention is paid to the conditions and principles of initiating this therapy.
Supporting agencies: The publication was supported by AO Bayer. PP-M_VER-RU-0015–1
About the Authors
Zh. D. Kobalava
Russian University of Peoples’ Friendship
Russian Federation
Russian Federation
Corresponding Member of the Russian Academy of Sciences, Professor, Doctor of Medical Sciences, Head of the Department of Internal Diseases with a course of cardiology and functional diagnostics named after V.S. Moiseev, Medical Institute, Peoples' Friendship University of Russia
Moscow, Russia
I. S. Nazarov
Russian University of Peoples’ Friendship
Russian Federation
Russian Federation
postgraduate student of the Department of Internal Diseases with a course of cardiology and functional diagnostics named after V.S. Moiseev, Medical Institute, Peoples' Friendship University of Russia.
Moscow, Russia
References
1. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Medical Journal. 2020;5(15):1–6. DOI: 10.21037/amj.2020.03.03
2. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023;118(17):3272–87. DOI: 10.1093/cvr/cvac013
3. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628
4. Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European Journal of Heart Failure. 2017;19(9):1095–104. DOI: 10.1002/ejhf.822
5. Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology. 2019;73(8):935–44. DOI: 10.1016/j.jacc.2018.11.049
6. Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology. 2021;6(5):499–507. DOI: 10.1001/jamacardio.2020.7585
7. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: The PARADIGM-HF Trial. JACC. Heart failure. 2016;4(10):816–22. DOI: 10.1016/j.jchf.2016.05.002
8. Lindmark K, Boman K, Stålhammar J, Olofsson M, Lahoz R, Studer R et al. Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study. ESC Heart Failure. 2021;8(3):2144–53. DOI: 10.1002/ehf2.13296
9. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology. 2015;12(4):220–9. DOI: 10.1038/nrcardio.2015.14
10. Villevalde S.V., Soloveva A.E. Decompensated heart failure with reduced ejection fraction: overcoming barriers to improve prognosis in the “vulnerable” period after discharge. Kardiologiia. 2021;61(12):82–93. DOI: 10.18087/cardio.2021.12.n1860
11. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure. 2021;27(4):387–413. DOI: 10.1016/j.cardfail.2021.01.022
12. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063
13. Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circulation: Heart Failure. 2020;13(6):e007132. DOI: 10.1161/CIRCHEARTFAILURE.120.007132
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368
15. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083
16. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiology. 2020;5(8):948–51. DOI: 10.1001/jamacardio.2020.0898
17. Wirtz HS, Sheer R, Honarpour N, Casebeer AW, Simmons JD, Kurtz CE et al. Real‐World Analysis of Guideline‐Based Therapy After Hospitalization for Heart Failure. Journal of the American Heart Association. 2020;9(16):e015042. DOI: 10.1161/JAHA.119.015042
18. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology. 2019;73(19):2365–83. DOI: 10.1016/j.jacc.2019.02.015
19. Srivastava PK, DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J et al. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. JACC: Heart Failure. 2021;9(1):28–38. DOI: 10.1016/j.jchf.2020.08.017
20. Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH et al. Heart Failure Drug Treatment – Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC: Heart Failure. 2023;11(1):1–14. DOI: 10.1016/j.jchf.2022.08.009
21. Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A et al. Care Gaps in Adherence to Heart Failure Guidelines. Clinical Inertia or Physiological Limitations? JACC: Heart Failure. 2020;8(9):725–38. DOI: 10.1016/j.jchf.2020.04.019
22. Takeuchi S, Kohno T, Goda A, Shiraishi Y, Kawana M, Saji M et al. Multimorbidity, guideline‐directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Failure. 2022;9(4):2500–10. DOI: 10.1002/ehf2.13954
23. Stolfo D, Sinagra G, Savarese G. Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review. 2022;8:e12. DOI: 10.15420/cfr.2021.34
24. Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L et al. Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata. European Journal of Heart Failure. 2022;24(6):1047–62. DOI: 10.1002/ejhf.2483
25. Chen X, Cui X, Thunström E, Pivodic A, Dahlström U, Fu M. Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. Clinical Research in Cardiology. 2021;110(7):1051–62. DOI: 10.1007/s00392-020-01790-y
26. Chen Y-L, Hang C-L, Su C-H, Wu P-J, Chen H-C, Fang H-Y et al. Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease. International Journal of Medical Sciences. 2021;18(12):2570–80. DOI: 10.7150/ijms.55119
27. Packer M, McMurray JJV. Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure. 2021;23(6):882–94. DOI: 10.1002/ejhf.2149
28. Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? JACC: Basic to Translational Science. 2022;7(5):504–17. DOI: 10.1016/j.jacbts.2021.10.018
29. Shen L, Jhund PS, Docherty KF, Vaduganathan M, Petrie MC, Desai AS et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal. 2022;43(27):2573–87. DOI: 10.1093/eurheartj/ehac210
30. D’Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. European Journal of Heart Failure. 2022;24(5):871–84. DOI: 10.1002/ejhf.2477
31. Brownell NK, Ziaeian B, Fonarow GC. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review. 2021;7:e18. DOI: 10.15420/cfr.2021.18
32. Dixit NM, Shah S, Ziaeian B, Fonarow GC, Hsu JJ. Optimizing Guidelinedirected Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review. 2021;15:e07. DOI: 10.15420/usc.2020.29
33. Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure – Optimizing Therapy With the Need for Speed. JAMA Cardiology. 2021;6(7):743–4. DOI: 10.1001/jamacardio.2021.0496
34. Cox ZL, Nandkeolyar S, Johnson AJ, Lindenfeld J, Rali AS. In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review. 2022;8:e21. DOI: 10.15420/cfr.2022.08
35. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2021;23(6):872–81. DOI: 10.1002/ejhf.2206
36. Miller RJH, Howlett JG, Fine NM. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology. 2021;37(4):632–43. DOI: 10.1016/j.cjca.2020.12.028
37. Njoroge JN, Cheema B, Ambrosy AP, Greene SJ, Collins SP, Vaduganathan M et al. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Failure Reviews. 2018;23(4):597–607. DOI: 10.1007/s10741-018-9697-9
38. Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC: Heart Failure. 2019;7(1):1–12. DOI: 10.1016/j.jchf.2018.06.011
39. Feng J-L, Qin X. Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews. 2021;26(1):81–9. DOI: 10.1007/s10741-019-09900-3
40. Bistola V, Simitsis P, Parissis J, Ouwerkerk W, Veldhuisen DJ, Cleland JG et al. Association between up‐titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure. 2021;23(7):1170–81. DOI: 10.1002/ejhf.2219
41. Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, Butler J et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology. 2019;74(15):1966–2011. DOI: 10.1016/j.jacc.2019.08.001
42. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128
43. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G et al. Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine. 2019;381(8):716–26. DOI: 10.1056/NEJMoa1801291
44. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. The New England Journal of Medicine. 2010;363(15):1419–28. DOI: 10.1056/NEJMoa0912613
45. Konstam MA. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31. DOI: 10.1001/jama.297.12.1319
46. Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD et al. Effect of ularitide on cardiovascular mortality in acute heart failure. The New England Journal of Medicine. 2017;376(20):1956–64. DOI: 10.1056/NEJMoa1601895
47. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S et al. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA. 2019;322(23):2292–302. DOI: 10.1001/jama.2019.18598
48. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiology. 2017;2(9):950–8. DOI: 10.1001/jamacardio.2017.2198
49. Wachter R, Senni M, Belohlavek J, Straburzynska‐Migaj E, Witte KK, Kobalava Z et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. European Journal of Heart Failure. 2019;21(8):998–1007. DOI: 10.1002/ejhf.1498
50. Pascual-Figal D, Wachter R, Senni M, Bao W, Noè A, Schwende H et al. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. JACC: Heart Failure. 2020;8(10):822–33. DOI: 10.1016/j.jchf.2020.05.012
51. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine. 2019;380(6):539–48. DOI: 10.1056/NEJMoa1812851
52. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019;139(19):2285–8. DOI: 10.1161/CIRCULATIONAHA.118.039331
53. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England Journal of Medicine. 2021;384(2):117–28. DOI: 10.1056/NEJMoa2030183
54. Tromp J, Ponikowski P, Salsali A, Angermann CE, Biegus J, Blatchford J et al. Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. European Journal of Heart Failure. 2021;23(5):826–34. DOI: 10.1002/ejhf.2137
55. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022;28(3):568–74. DOI: 10.1038/s41591-021-01659-1
56. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF). European Journal of Heart Failure. 2020;22(4):713–22. DOI: 10.1002/ejhf.1713
57. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAGHF). Circulation. 2022;146(4):289–98. DOI: 10.1161/CIRCULATIONAHA.122.059038
58. Charaya K, Shchekochikhin D, Andreev D, Dyachuk I, Tarasenko S, Poltavskaya M et al. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart. 2022;9(1):e001936. DOI: 10.1136/openhrt-2021-001936
59. Cox ZL, Collins SP, Aaron M, Hernandez GA, Iii ATM, Davidson BT et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. American Heart Journal. 2021;232:116–24. DOI: 10.1016/j.ahj.2020.10.071
60. The TIMI Study Group. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure - Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68). 2021. [Av. at: https://clinicaltrials.gov/ct2/show/NCT04363697]
61. Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. Journal of the American College of Cardiology. 2004;43(9):1534–41. DOI: 10.1016/j.jacc.2003.12.040
62. Chioncel O, Mebazaa A, Maggioni AP, Harjola V, Rosano G, Laroche C et al. Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry. European Journal of Heart Failure. 2019;21(11):1338–52. DOI: 10.1002/ejhf.1492
63. Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circulation: Heart Failure. 2015;8(4):741–8. DOI: 10.1161/CIRCHEARTFAILURE.114.001957
64. Rubio-Gracia J, Demissei BG, ter Maaten JM, Cleland JG, O’Connor CM, Metra M et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology. 2018;258:185–91. DOI: 10.1016/j.ijcard.2018.01.067
65. Kobalava Zh.D., Tolkacheva V.V., B. K. Sarlykov, F. E. Cabello, M. Bayarsaikhan, Diane ML et al. Integral assessment of congestion in patients with acute decompensated heart failure. Russian Journal of Cardiology. 2022;27(2):29–35. DOI: 10.15829/1560-4071-2022-4799
66. Rivas‐Lasarte M, Maestro A, Fernández‐Martínez J, López‐López L, Solé‐González E, Vives‐Borrás M et al. Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure. ESC Heart Failure. 2020;7(5):2621–8. DOI: 10.1002/ehf2.12842
67. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. New England Journal of Medicine. 2022;387(13):1185–95. DOI: 10.1056/NEJMoa2203094
68. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. European Heart Journal. 2023;44(5):411–21. DOI: 10.1093/eurheartj/ehac689
69. Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. European Heart Journal. 2023;44(1):41–50. DOI: 10.1093/eurheartj/ehac530
70. Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E et al. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced. European Journal of Heart Failure. 2023;25(1):117–27. DOI: 10.1002/ejhf.2728
71. Dębska-Kozłowska A, Książczyk M, Lelonek M. New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. Advances in Medical Sciences. 2022;67(1):95–102. DOI: 10.1016/j.advms.2022.01.003
72. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400(10367):1938–52. DOI: 10.1016/S0140-6736(22)02076-1
73. Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. New England Journal of Medicine. 2023;388(1):22–32. DOI: 10.1056/NEJMoa2211680
74. Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, Lainscak M et al. ‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor. ESC Heart Failure. 2021;8(6):4444–53. DOI: 10.1002/ehf2.13646
75. Logeart D, Berthelot E, Bihry N, Eschalier R, Salvat M, Garcon P et al. Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF). European Journal of Heart Failure. 2022;24(1):219–26. DOI: 10.1002/ejhf.2357
76. Hickey A, Suna J, Marquart L, Denaro C, Javorsky G, Munns A et al. Improving medication titration in heart failure by embedding a structured medication titration plan. International Journal of Cardiology. 2016;224:99–106. DOI: 10.1016/j.ijcard.2016.09.001
77. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2020;382(20):1883–93. DOI: 10.1056/NEJMoa1915928
78. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 2020;396(10266):1895–904. DOI: 10.1016/S0140-6736(20)32339-4
79. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022;400(10369):2199–209. DOI: 10.1016/S0140-6736(22)02083-9
80. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine. 2021;384(2):105–16. DOI: 10.1056/NEJMoa2025797
81. Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. European Journal of Heart Failure. 2021;23(8):1313–21. DOI: 10.1002/ejhf.2221
82. Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal. 2022;43(48):5006–16. DOI: 10.1093/eurheartj/ehac293
83. Pagnesi M, Baldetti L, Aimo A, Inciardi R, Tomasoni D, Vizzardi E et al. Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 2022;11(2):348. DOI: 10.3390/jcm11020348
84. Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, Van der Meer P et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2022;10(2):73–84. DOI: 10.1016/j.jchf.2021.09.004
Supplementary files
|
1. Фармакотерапия сердечной недостаточности с низкой фракцией выброса: препараты базовой терапии сердечной недостаточности и эпизод декомпенсации Дополнительные материалы | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(74KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kobalava Zh.D., Nazarov I.S. Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation. Kardiologiia. 2023;63(3):66-76. (In Russ.) https://doi.org/10.18087/cardio.2023.3.n2418
Views:
1690
Email this article 
Post a Comment 
